Astellas Pharma Inc.
ALPMY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | -1.07 | -0.05 | 0.02 |
| FCF Yield | 7.63% | 1.67% | 3.47% | 0.67% |
| EV / EBITDA | 21.58 | 21.04 | 32.19 | 27.41 |
| Quality | ||||
| ROIC | 3.22% | 2.80% | 3.09% | -3.65% |
| Gross Margin | 73.63% | 81.25% | 83.27% | 80.96% |
| Cash Conversion Ratio | 2.94 | 0.80 | 1.35 | -0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.83% | 8.76% | 7.99% | 8.35% |
| Free Cash Flow Growth | -96.46% | -54.00% | 398.78% | -62.77% |
| Safety | ||||
| Net Debt / EBITDA | 2.94 | 4.44 | 6.32 | 5.83 |
| Interest Coverage | 39.97 | 22.37 | 21.41 | -53.62 |
| Efficiency | ||||
| Inventory Turnover | 0.45 | 0.31 | 0.26 | 0.34 |
| Cash Conversion Cycle | 214.69 | 251.70 | 252.08 | 187.98 |